Research study Program year 2025 Source: CMS Open Payments

Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma

ClinicalTrials.gov NCT03761108

Research payments

$27,561,325

1,217 payments

Through program year 2025, $27,561,325 in research payments was reported against Phase 1/2 Fih Study of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) in Patients With Relapsed Or Refractory Multiple Myeloma, across 1,217 payments, paid by Regeneron Pharmaceuticals, Inc..

Paid by: Regeneron Pharmaceuticals, Inc.
ClinicalTrials.gov: NCT03761108

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$2,500,974	202
2024	Research	$3,371,049	181
2023	Research	$3,941,914	190
2022	Research	$8,963,294	281
2021	Research	$5,423,220	162
2020	Research	$3,360,873	201

Breakdown

Who paid Research payments · program years 2020–2025

Regeneron Pharmaceuticals, Inc. $27,561,325 1,217 payments

Who received the money Research payments · program years 2020–2025

The Ohio State University Organisation paid for research $3,690,505 79 payments
ICAHN School of Medicine at Mount Sinai Organisation paid for research $3,524,274 75 payments
Indiana University Organisation paid for research $3,238,765 66 payments
Ut Md Anderson Cancer Center Teaching hospital · TX $3,172,639 41 payments
University Of Miami Organisation paid for research $2,380,986 64 payments
Emory University Hospital Teaching hospital · GA $1,847,785 82 payments
Moffitt Cancer Center Teaching hospital · FL $1,573,549 153 payments
Swedish Medical Center Teaching hospital · WA $1,479,409 121 payments
The Trustees Of Columbia University In The City Of New York Organisation paid for research $1,348,309 53 payments
Karmanos Cancer Hospital Teaching hospital · MI $1,051,613 225 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

9 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.